E. Caronna, Rut Mas-de-les-Valls, G. Egeo, Manuel Millán Vázquez, Candela Nieves Castellanos, J. Membrilla, G. Vaghi, J. Rodríguez-Montolío, Neus Fabregat Fabra, Francisco Sánchez Caballero, Alex Jaimes, A. Muñoz-Vendrell, Renato Oliveira, G. Gárate, Yesica González Osorio, Daniel Guisado-Alonso, R. Ornello, Cem Thunstedt, Iris Fernández-Lázaro, A. Sánchez-Soblechero, A. Husøy, Beatriz Nunes Vicente, H. Basedau, Nuria Pilar Riesco Pérez, B. F. Pina, Catarina Fernandes, Alberto Andrés-López, Elisa Martins-Silva, S. Budrewicz, Pablo Ros Arlanzón, A. Caetano, V. Gallardo, Laura Gómez-Dabó, M. Torres-Ferrús, A. Alpuente, P. Torelli, C. Aurilia, Silvana Zapata, Raquel Lamas Pérez, Maria José Ruiz Castrillo, R. Icco, G. Sances, Sarah Broadhurst, H. Ong, J. Winstanley, Sonsoles Aranceta, Izaro Kortazar Zubizarreta, Amalia Echeverria Urabayen, Andrea Gómez García, S. Campoy, Ineˆs Marques, Elsa Parreira, V. González-Quintanilla, Á. Guerrero-Peral, Isabel Miró, Julia Peris-Subiza, V. Caponnetto, A. Straube, Alicia González-Martínez, Sonia Quintas, M. Sanchez-del-Rio, Erling Tronvik, Begoña Venegas Pérez, Agustin Oterino Durán, M. Rodrigues, A. Ramos, Yago Vaamonde Esteban, S. Cevoli, Bruno Colombo, Michele Trimboli, Fabio Frediani, Florindo D'Onofrio, M. Aguggia, Antonio Salerno, A. Carnevale, Maurizio Zucco, Maria Albanese, C. Finocchi, Angelo Ranieri, F. Zoroddu, Massimo Autunno, Jordi Sanahuja, Gonc¸alo Cabral, Isabel Beltran Blasco, Marta Waliszewska-Prosół, Liliana Pereira, A. Layos-Romero, I. Luzeiro, Laura Dorado, María Rocío Álvarez Escudero, A. May, A. López-Bravo, Isabel Pavão Martins, Christina Sundal, P. Irimia, A. L. Ros, A. Gago-Veiga, Fernando Velasco Juanes, Ruth Ruscheweyh, Simona Sacco, E. Cuadrado-Godia, David García-Azorín, Julio Pascual, Raquel Gil-Gouveia, M. Huerta-Villanueva, J. Rodríguez-Vico, J. V. Romero, V. Obach, S. Santos-Lasaosa, M. Ghadiri-Sani, Cristina Tassorelli, J. Díaz-de-Terán, Samuel Díaz Insa, Carmen Gonza´lez Oria, Piero Barbanti, P. Pozo-Rosich
2026.6.1CEPHALALGIA
सारांश
BackgroundThe International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs).MethodsThis was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category-migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4-6 MMD); insufficient control (>6 MMD)-after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group.ResultsOf the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0-55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3-28.0] and 15.0 [10.0-20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD.ConclusionsHigh standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.
साइटेशन फॉर्मेट
CARONNA, E., et al. Is achieving higher standards in real-world migraine care feasible with anti-cgrp monoclonal antibodies preventive therapies?: Insights from the eureka cohort. CEPHALALGIA, 2026, 46 6(6): 3331024261440370.